Directions for Use:
CogniCaps for Small Dogs: 60 Capsules
For dogs under 30 pounds, give one (1) capsule in the morning and one (1) capsule in the evening.
CogniCaps for Medium and Large Dogs: 120 Capsules
For dogs 30-60 pounds give one (1) capsule in the morning and two (2) capsules in the evening.
For dogs over 60 pounds give two (2) capsules in the morning and two (2) capsules in the evening.
The logic behind CogniCaps
Because there are so many individual dietary supplements that have shown efficacy in treating cognitive decline, veterinarians and their clients are often faced with the prospect of prescribing multiple separate supplements to produce a positive clinical response. In short, it often seems that there are too many potentially beneficial supplements to fit into one patient. It is also common practice to separate treatments for CCD into the categories of western and eastern medicine. Again, this conceptualization leads to the necessity of prescribing multiple supplements-both western (conventional) and eastern (non-conventional, holistic, etc.). Although pet owners often will administer multiple supplements to their senior dogs, it can be challenging. Also, it is unlikely that the average pet owner will administer multiple supplements to an asymptomatic middle-aged dog for preventive purposes. CogniCaps is a truly integrative supplement, combining a mixture of both western and eastern treatments in one small capsule.
How common is CCD?
According to Dr. Curtis Dewey, a veterinary neurologist with extensive knowledge on this subject, estimates of the prevalence of CCD generally vary between 14% and 35% of the pet dog population, in dogs 11-12 years old 28% and in dogs 15-16 years old 68%; however, he notes that those percentages are likely an under estimation of how common the disorder is. As with people with AD, the prevalence of CCD increases dramatically with age. Dogs may show evidence of brain changes as early as 6 years of age. Furthermore, many dogs with mild impairment will progress to moderate impairment and those with moderate disease often progress to severe impairment.
Is CCD treatable?
Fortunately, dogs with CCD are less likely to develop such severe impairment as occurs in people with AD. Affected dogs typically respond well to medical intervention, especially if instituted early in the disease process. There is also evidence in both AD and CCD that preventive measures such as dietary changes and environmental enrichment can both delay the onset and slow the progression of cognitive decline. This information suggests that simple preventive measures against CCD including dietary supplements as provided in CogniCaps, a proprietary formula developed by Dr. Dewey in conjunction with Dr. Fossum’s Pet Care, may be generally advisable in pet dogs as they near middle age.
Inhibits Ab production; antioxidant; anti inflammatory
Zinc is critical in the enzymatic processing of the amyloid precursor protein (APP) and in the enzymatic degradation of the amyloid-β (Aβ) peptide. Intracellular organelles, transporters, and metal binding proteins sequester and release zinc to maintain balance between second messenger signaling, transcriptional regulation, and pathological increases in the ion.
Evidence indicates that SAM-e levels are lower in patients with Alzheimer’s, which may compromise their metabolism and brain function. SAM-e is involved in glutathione production, a powerful antioxidant that works from within the cell. SAM-e increases the turnover of serotonin and may increase levels of dopamine and norepinephrine. It’s been shown to exhibit anti-inflammatory and analgesic effects
Inhibits antibody aggregation which reduces plaque formation; is an antioxidant and is anti inflammatory
BioCog* (reg. pending):
Inhibits antibody aggregation which reduces plaque formation; is an antioxidant and is anti inflammatory.
Patients with cognitive dysfunction often have reduced levels of Vitamin E in the CSF. Vitamin E is a potent antioxidant which protects neuronal myelin sheets from oxidation. These neurons are necessary for communication between the brain and muscles cells for coordination of motion.
Boosts the expression of brain-derived neurotrophic factor and nerve growth factor, increases synaptic plasticity and decreases the accumulation of amyloid β-protein. Has been shown to improve both spatial and non-spatial memory in aged mice.
Emerging data suggest that improper signaling of the innate immune pathway at the synapse leads to pathological synapse loss in age-related neurodegenerative diseases. Phosphatidylserine is a class of phospholipids found in cell membranes. Its levels and location within the brain can affect important signaling pathways for cell survival and communication.
Increased oxidative stress is implicated in the pathogenesis of age-related neurodegenerative diseases. CoQ10 reduces oxidative stress and amyloid pathology and improves behavioral performance in the mouse models of Alzheimer’s disease. CoQ10 treatment decreases brain levels of protein carbonyls, a marker of oxidative stress. CoQ10 treatment resulted in decreased plaque area and number in hippocampus and in overlying cortex.
Inactive Ingredients: Maltodextrine, Cornstarch, Soy.
Warning: Not for human consumption!
Keep out of the reach of children and animals. In case of accidental overdose, contact a health professional immediately.
Cautions: If animal’s condition worsens or does not improve, stop product administration and consult your veterinarian.
Safe use in pregnant animals or animals intended for breeding has not been proven.
Administer during or after the animal has eaten to reduce incidence of gastrointestinal upset.